Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
US9290539B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9290539-B2 |
| Application number | US-201414300991-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 10, 2014 |
| Priority date | May 17, 2011 |
| Publication date | Mar 22, 2016 |
| Grant date | Mar 22, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A MC1R peptide ligand-elastic vesicle complex for preventing skin maladies. The MC1R peptide ligand is modified by coupling the melanocortin 1 receptor (MC1R) ligand to a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, elastic vesicles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The MC1R peptide ligand-elastic vesicle complex is prepared as a patch or viscous emulsion that can be applied to human skin.
Opening claim text (preview).
What is claimed: 1. A patch comprising an impenetrable outer layer and a permeable inner layer, wherein the outer layer and inner layer form a reservoir for storing a pharmaceutical composition for treatment of melanoma, wherein the pharmaceutical composition comprises a melanocortin 1 receptor (MC1R) peptide ligand-elastic vesicle complex, wherein the elastic vesicle comprises a lipid bilayer, a surfactant, an outer core and an inner core, and wherein the MC1R peptide ligand is disposed within the inner core of the elastic vesicle, wherein said MC1R peptide ligand is selected from: (SEQ ID NO: 9) H-Tyr-Val-Nle-Gly-His-DNal(′2)-Arq-DTrp-Asp-Arg- Phe-Gly-NH2 9; (SEQ ID NO: 11) H-Tyr-Val-Nle-Gly-His-DPhe-Arg-DNal(2′)-Asp-Arg- Phe-Gly-NH2; (SEQ ID NO: 18) H-Tyr-Val-Leu-Gly-His-DPhe-Arg-DNal(2′)-Asp-Arg- Phe-Gly-NH2; or (SEQ ID NO: 19) H-Tyr-Val-Ile-Gly-His-DPhe-Arg-DNal(2′)-Asp-Arg- Phe-Gly-NH2. 2. The patch of claim 1 , wherein when the patch is applied to a skin of a human, the pharmaceutical composition permeates through a plurality of pores disposed in the inner layer and penetrates the skin, and wherein at least the MC1R peptide ligand-elastic vesicle complex passes through the skin. 3. The pharmaceutical composition of claim 2 , wherein a concentration of the MC1R peptide ligand in the blood stream is at most 10 ng/ml for a period of at least 4 hours. 4. The MC1R peptide ligand claim 1 , wherein the MC1R peptide ligand is an agonist of the MC1R receptor. 5. A viscous emulsion comprising a cosmeceutical composition for treatment of melanoma, said cosmeceutical composition comprising a melanocortin 1 receptor (MC1R) peptide ligand-elastic vesicle complex, wherein the elastic vesicle comprises a lipid bilayer, a surfactant, an outer core and an inner core, and wherein the MC1R peptide ligand is disposed within the inner core of the elastic vesicle, wherein said MC1R peptide ligand is selected from: (SEQ ID NO: 9) H-Tyr-Val-Nle-Gly-His-DNal(2′)-Arg-DTrp-Asp-Arg- Phe-Gly-NH 2 ; (SEQ ID NO: 11) H-Tyr-Val-Nle-Gly-His-DPhe-Arg-DNal(2′)-Asp-Arg- Phe-Gly-NH 2 ; (SEQ ID NO: 18) H-Tyr-Val-Leu-Gly-His-DPhe-Arg-DNal(2′)-Asp-Arg- Phe-Gly-NH 2 ; or (SEQ ID NO: 19) H-Tyr-Val-ILe-Gly-His-DPhe-Arg-DNal(2′)-Asp-Arg- Phe-Gly-NH 2 . 6. The viscous emulsion of claim 5 , wherein when the viscous emulsion is applied to a skin of a human, the cosmeceutical composition penetrates the skin, wherein at least the MC1R peptide ligand-elastic vesicle complex passes through the skin. 7. The cosmeceutical composition of claim 5 , wherein the concentration of the MC1R peptide ligand in the blood stream is at most 10 ng/ml for a period of at least 4 hours. 8. The MCIR peptide ligand of claim 5 , wherein the MC1R peptide ligand is an agonist of the MC1R receptor. 9. The viscous emulsion of claim 5 , wherein the viscous emulsion is a lotion, a cream, or a gel.
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor · CPC title
Alpha-melanotropin · CPC title
Melanocyte-stimulating hormone [MSH] · CPC title
Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads (for liquid bandages A61L26/00; radioactive dressings {A61N5/1029}) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.